Related Experiment Video
Updated: Aug 21, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Real-World Safety of Two Pulsed Field Ablation Catheters for Atrial Fibrillation: A MAUDE Analysis
Sami J Shoura1, Shreyas Singireddy1, Kyle Coombes2
1Department of Cardiology, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA.
Background:
Two pulsed field ablation (PFA) catheter systems for atrial fibrillation (AF) are widely adopted: the Affera Sphere-9 (Medtronic) and the Varipulse (Biosense Webster). Their comparative real-world safety is unknown.
Methods:
We searched the FDA MAUDE database (June 27, 2026) for all reports naming either catheter since U.S. release. After excluding duplicates and non-catheter components, 743 Affera and 361 Varipulse reports remained. Reports were classified by FDA Event Type (device- vs. patient-related) and complication status, with complications grouped by organ system. Proportions were compared with chi-square or Fisher exact tests in R 4.3.3.
Results:
Neurologic events were far more frequent among Varipulse reports (44.3 % vs. 14.8%; P < 0.001), driven by stroke (38.0% vs. 9.7%; P < 0.001). Cardiovascular events predominated among Affera reports (43.2% vs. 29.1%; P < 0.001), including ventricular fibrillation (52 vs. 1), heart block (8.7% vs. 1.4%; P < 0.001), and hypotension (5.5% vs. 0.8%; P<0.001); effusion/tamponade was more frequent with Varipulse (15.2% vs. 9.0%; P = 0.003). Complication-free reports were more frequent with Affera (35.3% vs. 21.1%; P < 0.001). Deaths did not differ (2.6% vs 1.4%; P = 0.30).
Conclusions:
These PFA systems show distinct reported safety signatures: neurologic/stroke-predominant for Varipulse and cardiovascular/arrhythmic (ventricular fibrillation, heart block) for Affera. Because MAUDE lacks procedural denominators, these proportions describe reported events, not incidence. Prospective, patient-level studies are needed to establish causation.
